Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Hernestål Boman, Jenny ^a   Norberg, Margareta ^a   Jansson, Jan Hakan ^a   Eliasson, Mats ^a,b   Eriksson, Jan W ^c   Lindahl, Bernt ^a   Johansson, Lars ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SUNDERBY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus type 2; Fibrinolysis; Plasminogen activator inhibitor 1; Population study; Tissue plasminogen activator; V sterbotten Intervention Programme; Von Willebrand factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MEDICAL EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POPULATION BASED CASE CONTROL STUDY; PROSPECTIVE STUDY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EARLY DIAGNOSIS; FASTING; FEMALE; FIBRINOLYSIS; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 84871103935     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-152     Document Type: Article

References (44)

1. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007, 298:2654-2664. 10.1001/jama.298.22.2654, 18073361.
2. Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003, 289:1785-1791. 10.1001/jama.289.14.1785, 12684356.
3. Norberg M, Stenlund H, Lindahl B, Andersson C, Weinehall L, Hallmans G, Eriksson JW. Components of metabolic syndrome predicting diabetes: no role of inflammation or dyslipidemia. Obesity 2007, 15:1875-1885. 10.1038/oby.2007.222, 17636107.
4. Meigs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep 2003, 3:73-79. 10.1007/s11892-003-0057-2, 12643149.
5. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, van der Poll T. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006, 55:1807-1812. 10.2337/db05-1543, 16731846.
6. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor?. J Thromb Haemost 2010, 8:1663-1669. 10.1111/j.1538-7836.2010.03910.x, 20492456.
7. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001, 15:44-54. 10.1016/S1056-8727(00)00132-X, 11259926.
8. Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005, 48:1017-1021. 10.1007/s00125-005-1715-5, 15778859.
9. Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol 2009, 8:48. 10.1186/1475-2840-8-48, 2743654, 19735543.
10. American Diabetes Association Implications of the United Kingdom prospective diabetes study. Diabetes Care 2000, 23(Suppl 1):S27-S31. American Diabetes Association.
11. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328.
12. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2003, 2:19. 10.1186/1475-2840-2-19, 328088, 14690546.
13. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008, 31:995-1000. 10.2337/dc07-1569, 18235054.
14. Heldgaard PE, Henriksen JE, Sidelmann JJ, Olivarius ND, Siersma VD, Gram JB. Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects. Scand J Prim Health Care 2011, 29:85-91. 10.3109/02813432.2011.565164, 3347946, 21438763.
15. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003, 108:420-425. 10.1161/01.CIR.0000080884.27358.49, 12860914.
16. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circulation 1996, 94:2057-2063. 10.1161/01.CIR.94.9.2057, 8901651.
17. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994, 47:513-524. 10.1016/0895-4356(94)90298-4, 7730877.
18. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137. 10.2337/diabetes.51.4.1131, 11916936.
19. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006, 113:1753-1759. 10.1161/CIRCULATIONAHA.106.616177, 16585388.
20. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003, 92:18J-26J.
21. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000, 31:26-32. 10.1161/01.STR.31.1.26, 10625711.
22. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, DeFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000, 20:2019-2023. 10.1161/01.ATV.20.8.2019, 10938026.
23. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 2008, 118:2533-2539. 10.1161/CIRCULATIONAHA.108.792986, 2746947, 19029465.
24. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001, 115:3-12. 10.1046/j.1365-2141.2001.03061.x, 11722403.
25. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228. 10.1016/S0140-6736(03)12255-6, 12547549.
26. Norberg M, Wall S, Boman K, Weinehall L. The Vasterbotten Intervention Programme: background, design and implications. Glob Health Action 2010, 3:4643.
27. Norberg M, Eriksson JW, Lindahl B, Andersson C, Rolandsson O, Stenlund H, Weinehall L. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med 2006, 260:263-271. 10.1111/j.1365-2796.2006.01689.x, 16918824.
28. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998, 16:171-176. 10.1080/028134398750003133, 9800231.
29. World Health Organisation Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation Part 1: Diagnosis and classification of diabetes mellitus 1999, Geneva: WHO/NCD/NCS/99.2, World Health Organisation.
30. Hernestal-Boman J, Jansson JH, Nilsson TK, Eliasson M, Johansson L. Long-term stability of fibrinolytic factors stored at -80 degrees C. Thromb Res 2010, 125:451-456. 10.1016/j.thromres.2009.12.007, 20053424.
31. Tada H, Tsukamoto M, Ishii H, Isogai S. A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells. Diabetes Res Clin Pract 1994, 24:33-39. 10.1016/0168-8227(94)90083-3, 7924884.
32. Kanaya AM, Wassel Fyr C, Vittinghoff E, Harris TB, Park SW, Goodpaster BH, Tylavsky F, Cummings SR. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006, 166:350-356. 10.1001/archinte.166.3.350, 16476877.
33. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800-803. 10.1038/nm0796-800, 8673927.
34. Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmad KA, Muniandy S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011, 10:23. 10.1186/1475-2840-10-23, 3064636, 21414238.
35. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788. 297006, 14679172.
36. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404. 10.1161/01.CIR.0000052617.91920.FD, 12551862.
37. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S, Cardinale C, Camin M, Chiaramonte E, De Sandre G, Lunardi C. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?. Atherosclerosis 1999, 143:81-90. 10.1016/S0021-9150(98)00281-0, 10208482.
38. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000, 49:1374-1380. 10.2337/diabetes.49.8.1374, 10923640.
39. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53:336-346. 10.2337/diabetes.53.2.336, 14747283.
40. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008, 99:995-1000.
41. Czekay RP, Wilkins-Port CE, Higgins SP, Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R, Higgins PJ. PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol 2011, 2011(Article ID:562481):9.
42. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997, 46:454-457. 10.1016/S0026-0495(97)90066-4, 9109854.
43. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998, 52:329-333. 10.1038/sj.ejcn.1600558, 9630382.
44. Nafziger AN, Lindvall K, Norberg M, Stenlund H, Wall S, Jenkins PL, Pearson TA, Weinehall L. Who is maintaining weight in a middle-aged population in Sweden? A longitudinal analysis over 10 years. BMC Public Health 2007, 7:108. 10.1186/1471-2458-7-108, 1904206, 17565692.